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CObjective: Indacaterol was evaluated versus placebo, formoterol, and
salmeterol in randomized controlled trials. No direct comparisons,
however, are available for indacaterol 150 g with formoterol or inda-
caterol 300 g with salmeterol. Indacaterol trial evidence was synthe-
ized to provide coherent estimates of indacaterol 150 g and inda-
caterol 300 g relative to formoterol, salmeterol, and tiotropium.
Methods: Four randomized controlled trials were combined with
Bayesian mixed treatment comparisons by using individual patient-
level data. End points of interest were trough forced expiratory volume
in 1 second (FEV1), St. George’s Respiratory Questionnaire (SGRQ) total
core and response (4 points), and Transition Dyspnea Index total
core and response (1 point). Results: Indacaterol 150 g demon-
strated a higher FEV1 than did formoterol at 12 weeks and 6 months
(0.10 L difference; 95% credible interval [CrI]  0.06 – 0.14), as did
indacaterol 300 g versus salmeterol (0.06 L difference at 12 weeks;
rI 0.02– 0.10; 0.06 L at 6 months; CrI 0.02– 0.11). Regarding SGRQ,ponders versus formoterol, as did indacaterol 300 g versus salme- O
o
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oi:10.1016/j.jval.2012.01.009terol. In comparison to tiotropium, indacaterol 150 g demonstrated
a greater proportion of responders (odds ratio  1.52 at 12 weeks; CrI
1.15–2.00). For Transition Dyspnea Index, indacaterol 150 g and
ormoterol showed a similar response. Indacaterol 300 g was more
fficacious than salmeterol (odds ratio  1.65 at 12 weeks; CrI 1.16 –
2.34). Overall, indacaterol 150 g showed the greatest efficacy for
SGRQ and indacaterol 300 g for FEV1 and Transition Dyspnea Index.
onclusion: Indacaterol is expected to be comparable to formoterol,
almeterol, and tiotropium, providing higher FEV1 than formoterol and
salmeterol and greater improvement in the SGRQ total score than
tiotropium. Indacaterol 150 g provided comparable improvement in
dyspnea, while indacaterol 300 g demonstrated the greatest response
verall.
eywords: chronic obstructive pulmonary disease, indacaterol, individ-
al patient data, mixed treatment comparison.
opyright © 2012, International Society for Pharmacoeconomics andndacaterol 150 g demonstrated a comparable proportion of re-
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Chronic obstructive pulmonary disease (COPD) is a progressive
lung disease resulting in gradual loss of lung function and
symptoms of chronic cough, sputum production, breathless-
ness, and impaired health status. Clinical practice guidelines
recommend that long-acting bronchodilators be used for pa-
tients with moderate or more severe disease if symptoms are
not relieved despite the use of short-acting bronchodilators [1].
Such bronchodilators include the twice-daily (BID) long-acting
2-agonists salmeterol and formoterol, once-daily (OD) long-
cting 2-agonist indacaterol, and the anticholinergic tiotro-
pium OD [1].
Indacaterol is a novel OD inhaled long-acting 2-agonist in-
icated for maintenance bronchodilator treatment of airflow
bstruction in adult patients with COPD. The recommended
ose in the European Union is one 150-g capsule OD, using the
nbrez Breezhaler inhaler, although the dose may be increased
* Address correspondence to: Jeroen P. Jansen, MAPI Consultancy,
E-mail: jjansen@mapigroup.com.
098-3015/$36.00 – see front matter Copyright © 2012, Internation
ublished by Elsevier Inc.n medical advice to a maximum dose of one 300-g capsule
D [2].
In an extensive phase III clinical trial program, indacaterol was
ompared with formoterol, open-label tiotropium, salmeterol, and
lacebo in four pivotal trials: INdacaterol: Value in COPD: Longer
erm Validation of Efficacy and Safety (INVOLVE) [3], INdacaterol
versus tiotropium] to Help Achieve New COPD treatment Excel-
ence (INHANCE) [4], INdacaterol efficacy evaLuation usInG 150 g
doses witH COPD paTients 2 (INLIGHT-2) [5], and INdacaterol
efficacy evaLuation usInG 150 g doses witH COPD paTients 1
(INLIGHT-1) [6]. No single randomized controlled trial (RCT) simul-
taneously compared all treatments of interest, and a direct head-
to-head comparison was not available for the comparisons of in-
dacaterol 150 g with formoterol and indacaterol 300 g with
almeterol.
The main objective of this study was to evaluate the relative
fficacy of indacaterol 150 g compared with formoterol 12 g
BID as well as indacaterol 300 g compared with salmeterol 50
Canal Street, Boston, MA 02114, USA.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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525V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 5 2 4 – 5 3 3g BID by synthesizing the results of the four RCTs. In doing so,
this study also generated efficacy estimates of indacaterol 150
and 300 g relative to tiotropium 18 g OD, salmeterol 50 g BID,
formoterol 12 g BID, and placebo. For this mixed treatment
omparison (MTC) [7,8], individual patient-level data (IPD) were
sed to allow for adjustment of possible confounding bias.
Methods
Evidence base
The IPD available from the four pivotal indacaterol RCTs formed
the evidence network as presented in Figure 1 (INVOLVE [3],
INHANCE [4], INLIGHT-2 [5], and INLIGHT-1 [6]), which represented
the only studies for which IPD were available. The INVOLVE
study evaluated indacaterol 300 and 600 g OD compared with
placebo and formoterol 12 g BID over 52 weeks. INHANCE as-
essed indacaterol 150 and 300 g OD compared with placebo
nd open-label tiotropium 18 g OD over 26 weeks. INLIGHT-2
compared indacaterol 150 g OD with placebo as well as with
almeterol 50 g BID over 26 weeks, and INLIGHT-1 evaluated
ndacaterol 150 g OD compared with placebo over 12 weeks.
Data for indacaterol 600 g from the INVOLVE study were in-
cluded in the analysis but results are not presented because the
dose is not licensed.
The four RCTs included had similar study designs, with all the
treatments administered double-blind except for the tiotropium
arm in the INHANCE study, which was open-label. Based on the
Cochrane Grades of Recommendation, Assessment, Development
and Evaluation system, the studies were considered of high qual-
ity, with the exception of the INHANCE study, which was consid-
ered of moderate quality given the open-label administration of
tiotropium [7]. The studies included between 416 patients
 
 
 
 
Salmeterol
50 µg BID
Formoterol 
12 µg BID
Indacaterol
300 µg OD
Tiotropium
18 µg OD
INHANCE
INLIGHT2
INLIGHT1
Indacaterol
150 µg OD
Placebo
INVOLVE
Fig. 1 – Overview of the evidence network available using
the four key trials. BID, twice-daily; INHANCE, INdacaterol
[versus tiotropium] to Help Achieve New COPD treatment
Excellence; INLIGHT-1, INdacaterol efficacy evaLuation usInG
150 g doses witH COPD paTients 1; INLIGHT-2, INdacaterol
efficacy evaLuation usInG 150 g doses witH COPD paTients
2; INVOLVE, INdacaterol: Value in COPD: Longer Term
Validation of Efficacy and Safety; OD, once-daily.(INLIGHT-1) and 1732 patients (INVOLVE). The inclusion criteriawere consistent across studies: patients were at least 40 years old
with a diagnosis of COPD, a forced expiratory volume in 1 second
(FEV1) of 30% or more and less than 80% of predicted, FEV1/forced
vital capacity of less than 70%, and a smoking history of at least 20
pack-years. Patients were excluded if they had been hospitalized
within 6 weeks prior to the trial or during the run-in period. During
the trial period, patients using fixed-dose combinations of 2-ago-
ists and inhaled corticosteroids were switched to equivalent in-
aled corticosteroid monotherapy (at a dose and regimen to re-
ain consistent throughout the study). Rescue medication with
albutamol was also permitted as needed.
Outcomes of interest
The outcomes of interest were evaluated at 12 weeks and 6
months: FEV1 at 24 hours postdose (“trough”; mean of the values
assessed at 23 hours 10 minutes and 23 hours 45 minutes follow-
ing the previous morning dose), health status as assessed by the
St. George’s Respiratory Questionnaire (SGRQ) total score, the pro-
portion of patients with a clinically relevant response in SGRQ
(4-point decrease from baseline) [10], dyspnea as assessed by the
Transition Dyspnea Index (TDI) total score, and the proportion of
patients with a clinically relevant response in TDI (score of 1
point) [11]. FEV1 was selected because it represented the primary
outcome in all four trials. The remaining outcomes were chosen
because they reflect patient-relevant secondary outcomes mea-
sured by validated instruments for which data were available
across the four RCTs.
Analysis
For each of the end points of interest, IPD from the RCTs were used
to perform a Bayesian MTC [8,9,12–16]. Analyses within the Bayes-
ian framework involve data, a likelihood distribution, a model
with parameters, and a prior distribution [17].
The model for a patient-level MTC relates the IPD from each of
the studies to the basic parameters reflecting the relative treat-
ment effects of each intervention compared with placebo. Based
on these basic parameters, the relative efficacy estimates between
all the interventions of interest can be obtained according to func-
tional relations between the basic parameters of each intervention
[8,12,13]. Inconsistency in an MTC occurs when the distribution of
treatment effect modifiers is not evenly distributed across com-
parisons [12–15]. To minimize inconsistency and possible con-
founding bias, treatment by covariate interactions were incorpo-
rated in the models [18]. Covariates potentially causing bias were
selected on the basis of clinical expertise and evaluation whether
these covariates were indeed effect modifiers of any of the treat-
ments under study in the individual trials. In addition to treat-
ment and study effects, the following covariates and treatment by
covariate interactions were included in the model: baseline value
of outcome, proportion of current smokers, reversibility to short-
acting 2-agonist, and reversibility to short-acting anticholinergic.
For trough FEV1, SGRQ total score, and TDI total score, linear mod-
els with normal likelihood distributions were used. A logistic
model with a Bernoulli likelihood distribution was used to analyze
the proportion of patients with a clinically relevant response in
SGRQ and TDI. In the Appendix found at doi:10.1016/j.jval.
2012.01.009, details of the models are presented.
To avoid influencing the results of the analysis based on prior
beliefs, noninformative prior distributions were used for the
model parameters to be estimated (normal distributions with
mean 0 and a variance of 100). The deviance information criterion,
which provides a measure of model fit that penalizes model com-
plexity, was used to select fixed-effects models over random-ef-
fects models [19,20]. Sensitivity analyses were performed regard-
ing the noninformative prior distributions for the parameters to be
estimated, and results were not affected. (Because a fixed-effects
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526 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 5 2 4 – 5 3 3model was deemed appropriate, no heterogeneity parameter
needed to be estimated. Typically, only a heterogeneity parameter
is sensitive to the definition of the corresponding noninformative
prior.).
All models were analyzed by using Markov Chain Monte
Carlo techniques with WinBUGS 1.4.1, which was programmed
by using R (Version 2.8.1). For each analysis, the Gelman-Rubin
statistic (as modified by Brooks and Gelman [21]) was visually
inspected on the basis of a graphical plot of the starting itera-
tion and range illustrating the approximate point of conver-
gence. The posterior distribution for the relative efficacy of
indacaterol 150 and 300 g compared with the treatment alter-
atives was summarized (difference in FEV1/SGRQ/TDI total
cores or odds ratio for the proportion of patients with clinically
elevant response in SGRQ and TDI) with the median as a mea-
ure of the point estimate and the 2.5th and 97.5th percentile to
eflect the 95% credible interval. Ninety-five percent credible
ntervals represent the 95% probability that the true underlying
ffect lies in the interval specified. The probability that each
reatment was the best is presented in addition to the probabil-
ty that indacaterol 150 and 300 g were better than the alter-
atives. In the online supplemental material to this article
ound at doi:10.1016/j.jval.2012.01.009, the model parameter es-
imates are provided.
Results
Study and patient characteristics
Table 1 provides information on the patient characteristics for
the four included RCTs. Across the studies, the patients were
predominantly Caucasian (range from 76% and 94%), mostly
male (range from 51% to 82%), and with an average age range
between 63 and 64 years. The baseline lung function was com-
parable across the studies, with the average FEV1 percentage
redicted ranging from 53% to 56% and the average FEV1/forced
vital capacity percentage ranging from 51% to 54%. The duration
of COPD was also similar across the studies, with the average
ranging from 6.4 to 7.4 years. Across the studies, there was some
variation in the proportion of patients with severe or very
severe COPD (as defined by GOLD guidelines), ranging from
38% to 46%. Reversibility to short-acting 2-agonists as a per-
entage of prebronchodilator FEV1 ranged from 11% to 17%.
round half of the patients were current smokers (range from
0% to 53%), with an average smoking history of between 40 and
1 pack-years. Finally, the proportion of patients using concom-
tant inhaled corticosteroids varied across the studies from 29%
o 56%.
Mixed treatment comparison
Table 2 presents the individual study summary statistics based on
the IPD sets for the outcomes of interest, and Tables 3 to 5 present
he corresponding results obtained with the MTC.
Forced expiratory volume in 1 second
All interventions compared were more efficacious than placebo
regarding FEV1 (Table 3). Indacaterol 150 g resulted in a higher
EV1 at 12-weeks and 6-months follow-up compared with formot-
erol 12 g and salmeterol 50 g. Furthermore, indacaterol 150 g
as at least as efficacious as tiotropium 18 g. Similar compara-
ive estimates were observed for indacaterol 300 g, supporting
higher FEV1 at 12 weeks and 6 months compared with formoterol
and salmeterol, as well as comparable estimates to tiotropium.
Indacaterol 300 g is expected to be the most efficacious in termsf FEV1.T IN IN IN IN N B ti u * †
Table 2 – Individual study results for each study at baseline, 12 wk, and 6 mo by outcome.
Outcome Placebo Indacaterol 150 g
OD
Indacaterol 300 g
OD
Formoterol 12 g
BID
Tiotropium 18 g
OD
Salmeterol 50 g
BID
N Mean (SD) N Mean (SD) N Mean (SD) N Mean (SD) N Mean (SD) N Mean (SD)
FEV1
INVOLVE
Bsl 371 1.32 (0.46) 389 1.31 (0.43) 379 1.31 (0.43)
12 wk 371 1.35 (0.49) 389 1.40 (0.48) 379 1.40 (0.48)
6 mo 327 1.34 (0.48) 365 1.42 (0.49) 353 1.37 (0.47)
INHANCE
Bsl 376 1.31 (0.48) 389 1.31 (0.50) 389 1.24 (0.48) 393 1.24 (0.48)
12 wk 376 1.30 (0.47) 389 1.47 (0.54) 389 1.37 (0.52) 393 1.37 (0.52)
6 mo 317 1.29 (0.48) 349 1.43 (0.54) 361 1.50 (0.59) 356 1.35 (0.51)
INLIGHT-2
Bsl 316 1.32 (0.49) 320 1.31 (0.48) 316 1.31 (0.48)
12 wk 316 1.29 (0.49) 320 1.46 (0.58) 316 1.40 (0.53)
6 mo 274 1.27 (0.46) 300 1.43 (0.57) 290 1.39 (0.53)
INLIGHT-1
Bsl 189 1.34 (0.59) 201 1.34 (0.60)
12 wk 189 1.35 (0.55) 201 1.49 (0.63)
6 mo
SGRQ total score
INVOLVE
Bsl 347 43.61 (17.8) 372 44.47 (17.09) 359 44.32 (17.33)
12 wk 347 41.60 (18.48) 372 38.50 (17.88) 359 39.10 (18.38)
6 mo 294 41.02 (18.15) 330 37.93 (18.49) 318 38.87 (18.36)
INHANCE
Bsl 347 45.69 (17.29) 368 45.39 (19.12) 375 44.64 (18.68) 374 44.56 (18.11)
12 wk 347 42.68 (18.31) 368 39.85 (19.62) 375 39.50 (18.91) 374 41.03 (18.40)
6 mo 319 41.13 (17.68) 346 37.94 (18.98) 360 38.33 (19.01) 357 40.22 (19.12)
INLIGHT-2
Bsl 294 43.62 (17.75) 309 43.60 (18.66) 300 43.15 (18.47)
12 wk 294 42.38 (19.55) 309 35.94 (19.42) 300 37.66 (18.49)
6 mo 274 41.74 (19.21) 299 37.07 (20.20) 291 37.46 (18.16)
INLIGHT-1
Bsl 187 48.73 (18.86) 199 50.09 (18.90)
12 wk 187 47.59 (19.17) 199 43.88 (19.74)
6 mo
TDI total score
INVOLVE
Bsl 343 6.52 (2.21) 364 6.61 (2.12) 359 6.47 (2.06)
12 wk 343 0.87 (3.15) 364 2.11 (3.07) 359 1.66 (2.96)
6 mo 284 0.98 (3.07) 325 2.25 (3.10) 316 1.71 (3.11)
(continued on next page)
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Table 2 (continued)
Outcome Placebo Indacaterol 150 g
OD
Indacaterol 300 g
OD
Formoterol 12 g
BID
Tiotropium 18 g
OD
Salmeterol 50 g
BID
N Mean (SD) N Mean (SD) N Mean (SD) N Mean (SD) N Mean (SD) N Mean (SD)
INHANCE
Bsl 326 6.57 (2.37) 355 6.56 (2.38) 363 6.52 (2.32) 360 6.57 (2.23)
12 wk 326 1.19 (3.09) 355 2.09 (3.27) 363 2.40 (3.12) 360 1.89 (3.05)
6 mo 309 1.39 (3.19) 343 2.33 (3.24) 353 2.67 (3.17) 349 2.18 (3.25)
INLIGHT-2
Bsl 286 6.63 (2.01) 303 6.74 (2.10) 295 6.68 (2.21)
12 wk 286 0.87 (2.98) 303 2.37 (3.28) 295 1.62 (2.97)
6 mo 272 1.31 (3.46) 297 2.28 (3.60) 288 2.08 (3.31)
N % N % N % N % N % N %
% SGRQ  4 points*
INVOLVE
12 wk 347 41 372 52 359 52
6 mo 294 40 330 55 318 51
INHANCE
12 wk 347 45 368 52 375 50 374 45
6 mo 319 46 346 58 360 53 357 47 300 47
INLIGHT-2
12 wk 294 39 309 58 300 47
6 mo 274 38 299 53 291 49
INLIGHT-1
12 wk 187 33 199 52
6 mo
% TDI  1 point†
INVOLVE
12 wk 343 40 364 63 359 53
6 mo 284 41 325 59 316 54
INHANCE
12 wk 326 42 355 59 363 66 360 55
6 mo 309 47 343 62 353 71 349 57
INLIGHT-2
12 wk 286 40 303 60 295 52
6 mo 272 45 297 57 288 54
Notes. Minor differences in the outcomes compared with the study publications are present because of missing data in the covariate values for this analysis. N is the sample size of data included
in analysis. Mean (SD) presented for continuous outcomes and proportion (%) of patients with event presented for dichotomous outcomes.
BID, twice daily; Bsl, baseline; FEV1, forced expiratory volume in 1 s; INHANCE, INdacaterol [versus tiotropium] to Help Achieve New COPD treatment Excellence; INLIGHT-1, INdacaterol efficacy
evaLuation usInG 150 g doses witH COPD paTients 1; INLIGHT-2, INdacaterol efficacy evaLuation usInG 150 g doses witH COPD paTients 2; INVOLVE, INdacaterol: Value in COPD: Longer Term
Validation of Efficacy and Safety; OD, once daily; SGRQ, St. George’s Respiratory Questionnaire; TDI, Transition Dyspnea Index.
* SGRQ clinically relevant improvement  4-point improvement.
† TDI clinically relevant improvement  1-point improvement.
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Indacaterol 150 g, indacaterol 300 g, and formoterol were
ore efficacious than placebo for both the SGRQ total score and
GRQ clinically relevant response (Table 4). Tiotropium was
ore efficacious than placebo in terms of the total score only at
2 weeks. Salmeterol was more efficacious than placebo in
erms of the SGRQ total score at both 12 weeks and 6 months.
or SGRQ clinically relevant response, a significant difference
ith salmeterol over placebo was observed only at 6 months.
ndacaterol 150 g and indacaterol 300 g were more efficacious
han tiotropium 18 g in terms of total score. Relative to formot-
erol 12 g, a greater improvement in the SGRQ total score was
observed with indacaterol 150 g and indacaterol 300 g, but
uncertainty in the estimates suggest that the finding is ambig-
uous. Indacaterol 150 g and indacaterol 300 g showed similar
mprovements in the SGRQ total score as did salmeterol.
At 12 weeks, a greater proportion of patients experienced a
linically relevant response with indacaterol 150 g compared
ith salmeterol. The effect with indacaterol 300 g was less pro-
nounced. Overall, indacaterol 150 g was the most efficacious in
erms of SGRQ.
Transition dyspnea index
All the interventions were more efficacious than placebo re-
garding the TDI total score and response (Table 5). In terms of
TDI at 12 weeks, indacaterol 150 g was at least as efficacious as
almeterol, formoterol, and tiotropium. At 6 months, the differ-
nces favoring indacaterol 150 g were smaller than at 12
weeks. Indacaterol 300 g was more efficacious than tiotro-
ium, salmeterol, and formoterol at 12 weeks for both total
core and proportion of patients with a clinically relevant re-
ponse. At 6 months, indacaterol 300 g was more efficacious
han tiotropium and formoterol and comparable to salmeterol
n terms of the TDI score, but showed a greater proportion of
Table 3 – Results of patient-level mixed treatment compari
Treatment Comparator Difference in FEV1 at 1
Mean
(95% CrI)
Probability tha
treatment is
better than
comparator
Tiotropium
18 g
Placebo 0.13 (0.10–0.16) 99%
Salmeterol
50 g
Placebo 0.11 (0.07–0.15) 99%
Formoterol
12 g
Placebo 0.06 (0.03–0.10) 99%
Indacaterol
150 g
Placebo 0.16 (0.14–0.19) 99%
Indacaterol
300 g
Placebo 0.17 (0.15–0.19) 99%
Indacaterol
150 g
Tiotropium 18 g 0.03 (0.00–0.06) 97%
Indacaterol
150 g
Salmeterol 50 g 0.05 (0.02–0.09) 99%
Indacaterol
150 g
Formoterol 12 g 0.10 (0.06–0.14) 99%
Indacaterol
300 g
Tiotropium 18 g 0.04 (0.00–0.07) 98%
Indacaterol
300 g
Salmeterol 50 g 0.06 (0.02–0.10) 99%
Indacaterol
300 g
Formoterol 12 g 0.10 (0.07–0.14) 99%
CrI, credible interval; FEV1, forced expiratory volume in 1 s.atients with a clinically relevant response relative to tiotro-ium and salmeterol. Overall, indacaterol 300 g was the most
efficacious in terms of TDI.
Discussion
The main aim of this study was to assess the relative efficacy of
indacaterol 150g compared with formoterol and indacaterol 300g
ompared with salmeterol in patients with moderate to severe COPD.
ased on IPD from four RCTs, indacaterol 150 and 300 g are more
fficacious than formoterol and salmeterol regarding FEV1 and at
east as efficacious as tiotropium. Patients receiving indacaterol ex-
erienced greater improvements in the SGRQ total score in compar-
son to tiotropium, which corresponded to a higher proportion of
atients with a clinically relevant improvement for indacaterol 150
g. In comparison to formoterol and salmeterol, SGRQ results were
comparable. The clinically relevant response in dyspnea with inda-
caterol 150 g was at least as good as with the other interventions,
with indacaterol 300 g showing an even greater improvement than
indacaterol 150 g compared with the alternatives.
Although each of the included RCTs provides evidence for the
relative efficacy of indacaterol versus an active comparator, none
of the studies included both doses of indacaterol compared with
all the available comparator interventions. However, all four RCTs
form an evidence network given the presence of common compar-
ators across trials (see Fig. 1). As a result, it is possible to synthesize
the results of the four RCTs by means of a Bayesian MTC [12–15].
This framework provides the relative effectiveness for the com-
peting interventions as well as the probability of being the better
treatment, which naturally supports decision making and is intu-
itive for decision-makers [15]. The internal validity of an MTC is
contingent upon the extent of confounding bias due to similarity
and consistency violations [12–15,18].
Overall, the RCTs were pivotal studies of the indacaterol clini-
cal development program and were considered of high quality,
for trough FEV1.
Difference in FEV1 at 6 mo
robability
that
reatment
is best
Mean
(95% CrI)
Probability that
treatment is
better than
comparator
Probability
that
treatment
is best
0% 0.15 (0.11–0.18) 99% 7%
0% 0.11 (0.07–0.15) 99% 0%
0% 0.06 (0.03–0.09) 99% 0%
38% 0.16 (0.13–0.19) 99% 27%
62% 0.17 (0.14–0.19) 99% 66%
0.01 (0.02 to 0.05) 77%
0.05 (0.01–0.09) 99%
0.10 (0.06–0.14) 99%
0.02 (0.01 to 0.06) 90%
0.06 (0.02–0.11) 99%
0.11 (0.08–0.14) 99%son
2 wk
t P
twith the exception of the INHANCE study, in which the open-label
wp
b
s
w
M
uest
530 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 5 2 4 – 5 3 3evaluation of tiotropium reflects a potential limitation of the evi-
dence base. Despite this limitation, Donohue et al. [4] reported that
the treatment effect of tiotropium compared with placebo was
similar to previous results where tiotropium was blinded for
trough FEV [22–24]. With an MTC, randomization holds only
Table 4 – Results of patient-level mixed treatment compari
Treatment Comparator Difference in SGRQ total sc
Mean
(95% CrI)
Probabili
that
treatmen
better th
compara
Tiotropium
18 g
Placebo 1.62 (3.17 to 0.07) 98%
Salmeterol
50 g
Placebo 3.43 (5.33 to 1.51) 99%
Formoterol
12 g
Placebo 2.59 (4.29 to 0.89) 99%
Indacaterol
150 g
Placebo 4.23 (5.36 to 3.07) 99%
Indacaterol
300 g
Placebo 3.30 (4.47 to 2.11) 99%
Indacaterol
150 g
Tiotropium 18 g 2.62 (4.23 to 1.06) 99%
Indacaterol
150 g
Salmeterol 50 g 0.81 (2.74 to 1.11) 80%
Indacaterol
150 g
Formoterol 12 g 1.65 (3.57 to 0.28) 95%
Indacaterol
300 g
Tiotropium 18 g 1.68 (3.29 to 0.07) 98%
Indacaterol
300 g
Salmeterol 50 g 0.13 (2.01 to 2.31) 46%
Indacaterol
300 g
Formoterol 12 g 0.71 (2.40 to 0.95) 80%
Treatment Comparator SGRQ response at 12
OR
(95% CrI)
Probability
treatment
better than
comparator
Tiotropium
18 g
Placebo 1.19 (0.91–1.56) 91%
Salmeterol
50 g
Placebo 1.32 (0.97–1.81) 96%
Formoterol
12 g
Placebo 1.46 (1.12–1.94) 99%
Indacaterol
150 g
Placebo 1.81 (1.49–2.19) 99%
Indacaterol
300 g
Placebo 1.49 (1.22–1.83) 99%
99%
Indacaterol
150 g
Tiotropium 18 g 1.52 (1.15–2.00) 99%
Indacaterol
150 g
Salmeterol 50 g 1.37 (1.01–1.86) 98%
Indacaterol
150 g
Formoterol 12 g 1.24 (0.90–1.69) 90%
Indacaterol
300 g
Tiotropium 18 g 1.25 (0.95–1.66) 94%
Indacaterol
300 g
Salmeterol 50 g 1.13 (0.80–1.61) 75%
Indacaterol
300 g
Formoterol 12 g 1.02 (0.77–1.34) 55%
CrI, credible interval; OR, odds ratio; SGRQ, St. George’s Respiratory Q1
ithin a trial and not across trials. As a result, there is the risk that catients who were assigned the different trials are not compara-
le. If the distribution of relative treatment-effect modifiers is not
imilar across trials comparing different interventions in the net-
ork of studies, the similarity and consistency assumptions in an
TC are violated and results will be biased [12–15,18]. This bias
for SGRQ.
t 12 wk Difference in SGRQ total score at 6 mo
Probability
that
treatment
is best
Mean (95% CrI) Probability
that
treatment is
better than
comparator
Probability
that
treatment
is best
0% 1.29 (3.03 to 0.48) 92% 0%
21% 3.51 (5.66 to 1.36) 99% 24%
2% 2.59 (4.53 to 0.65) 99% 4%
72% 4.21 (5.67 to 2.76) 99% 62%
5% 3.43 (4.79 to 2.05) 99% 10%
2.93 (4.72 to 1.13) 99%
0.70 (2.82 to 1.44) 74%
1.62 (3.90 to 0.62) 92%
2.14 (3.93 to 0.36) 99%
0.09 (2.33 to 2.50) 47%
0.83 (2.72 to 1.05) 81%
SGRQ response at 6 mo
bability
that
atment
is best
OR
(95% CrI)
Probability
treatment
better than
comparator
Probability
that
treatment
is best
0% 1.17 (0.89–1.54) 87% 0%
2% 1.61 (1.17–2.21) 100% 21%
7% 1.39 (1.03–1.88) 99% 4%
89% 1.82 (1.45–2.26) 99% 69%
2% 1.54 (1.25–1.92) 99% 6%
99%
1.55 (1.16–2.07) 99%
1.13 (0.82–1.55) 77%
1.31 (0.92–1.86) 93%
1.32 (0.99–1.74) 97%
0.96 (0.66–1.38) 40%
1.11 (0.82–1.49) 75%
ionnaire.son
ore a
ty
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an
tor
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trean be limited by adjusting for these differences by incorporating
531V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 5 2 4 – 5 3 3treatment by covariate interactions in the statistical models used
[18]. Often MTCs are performed on the basis of aggregate-level
data (AD), and the adjustment for confounding is attempted with
reported average values for the patient covariates. A challenge
with meta-regression models using AD is that the association be-
tween a patient-level covariate and the relative treatment effect of
the studied interventions at the study level may not reflect the
Table 5 – Results of patient-level mixed treatment compari
Treatment Comparator Difference in TDI total sco
Mean
(95% CrI)
Probability th
treatment i
better than
comparato
Tiotropium
18 g
Placebo 0.81 (0.40–1.23) 99%
Salmeterol
50 g
Placebo 0.62 (0.13–1.10) 99%
Formoterol
12 g
Placebo 0.79 (0.38–1.21) 99%
Indacaterol
150 g
Placebo 1.17 (0.84–1.48) 99%
Indacaterol
300 g
Placebo 1.30 (0.98–1.61) 99%
Indacaterol
150 g
Tiotropium 18 g 0.35 (0.06 to 0.78) 95%
Indacaterol
150 g
Salmeterol 50 g 0.55 (0.08–1.03) 99%
Indacaterol
150 g
Formoterol 12 g 0.38 (0.12 to 0.86) 93%
Indacaterol
300 g
Tiotropium 18 g 0.48 (0.06–0.90) 99%
Indacaterol
300 g
Salmeterol 50 g 0.68 (0.15–1.21) 99%
Indacaterol
300 g
Formoterol 12 g 0.50 (0.09–0.91) 99%
Treatment Comparator TDI response at 1
OR
(95% CrI)
Probability th
treatment i
better than
comparator
Tiotropium
18 g
Placebo 1.70 (1.29–2.21) 99%
Salmeterol
50 g
Placebo 1.58 (1.17–2.14) 99%
Formoterol
12 g
Placebo 1.67 (1.27–2.21) 99%
Indacaterol
150 g
Placebo 2.06 (1.67–2.57) 99%
Indacaterol
300 g
Placebo 2.60 (2.12–3.21) 99%
Indacaterol
150 g
Tiotropium 18 g 1.22 (0.92–1.62) 92%
Indacaterol
150 g
Salmeterol 50 g 1.31 (0.97–1.78) 96%
Indacaterol
150 g
Formoterol 12 g 1.24 (0.89–1.72) 90%
Indacaterol
300 g
Tiotropium 18 g 1.53 (1.17–2.03) 99%
Indacaterol
300 g
Salmeterol 50 g 1.65 (1.16–2.34) 99%
Indacaterol
300 g
Formoterol 12 g 1.56 (1.18–2.05) 55%
CrI, credible interval; OR, odds ratio; TDI, Transition Dyspnea Index.individual-level effect modification of that covariate [16,37–42]. Assuch, it is possible that even after adjustment for imbalances
across trials, MTC results can still be biased. In the current analy-
sis, an MTC with adjustment for differences in effect modifiers
across comparisons based on patient-level data was performed.
Given the advantage of IPD over AD to adjust for similarity and
consistency violations in an MTC, the former might be considered
the gold standard for the synthesis of a network of RCTs. (Of
for TDI.
12 wk Difference in TDI total score at 6 mo
Probability
that
treatment
is best
Mean
(95% CrI)
Probability that
treatment is
better than
comparator
Probability
that
treatment
is best
1% 0.79 (0.36–1.22) 99% 1%
0% 0.90 (0.36–1.43) 99% 10%
0% 0.73 (0.28–1.18) 99% 0%
27% 0.95 (0.60–1.31) 99% 4%
72% 1.28 (0.95–1.62) 99% 85%
0.17 (0.28 to 0.61) 77%
0.05 (0.46 to 0.58) 58%
0.22 (0.33 to 0.76) 79%
0.50 (0.05–0.93) 99%
0.38 (0.21 to 0.98) 90%
0.55 (0.10–1.00) 99%
TDI response at 6 mo
Probability
that
treatment
is best
OR
(95% CrI)
Probability that
treatment is
better than
comparator
Probability
that
treatment
is best
0% 1.41 (1.07–1.85) 99% 0%
0% 1.54 (1.12–2.10) 99% 1%
0% 1.78 (1.33–2.38) 99% 2%
4% 1.68 (1.35–2.10) 99% 0%
96% 2.36 (1.90–2.94) 99% 97%
1.20 (0.90–1.59) 89%
1.10 (0.80–1.49) 72%
0.95 (0.67–1.34) 38%
1.68 (1.25–2.24) 99%
1.53 (1.07–2.21) 99%
1.33 (0.99–1.78) 97%son
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532 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 5 2 4 – 5 3 3imbalance in unmeasured effect modifiers across comparisons;
accordingly, an RCT with all interventions of interest included is
less prone to confounding bias.) Although we presented the re-
sults based on the MTC meta-regression models, it is important to
note that when we also ran models without covariate adjustment,
the relative efficacy estimates were comparable to those obtained
for the models with covariate adjustment.
The current MTC included four key studies; it does not consider
the complete body of published RCT evidence regarding formot-
erol, salmeterol, and formoterol, which can be considered a limi-
tation. However, IPD were not available to the authors for the other
studies. A literature search identified close to 40 RCTs evaluating
formoterol, salmeterol, or tiotropium. Overall, these studies were
relatively similar in terms of study characteristics as compared
with the indacaterol studies. Most of the published studies were
placebo-controlled trials and were double-blind and double
dummy. The INHANCE study in the current analysis, however,
was open label [4]. The studies in the literature were predomi-
nantly multicenter trials in Europe and North America, whereas
the indacaterol trials INVOLVE and INSIGHT-2 also included some
study centers in South America, Africa, and Asia [3,5]. The patients
included in the indacaterol studies seem representative of those
included in other studies. All studies required patients to have a
clinical diagnosis of COPD, to be 40 years of age or older, and with-
out a history of exacerbations or hospitalizations in the past 4 to 6
weeks. These selection criteria were consistent with the inda-
caterol studies. However, patients in the other studies typically
had an FEV1 predicted of less than 60% to 70%, while the inda-
caterol studies included patients with an FEV1 predicted of less
than 80%. Furthermore, most studies required that patients had at
least 10 pack-years of smoking history, whereas the indacaterol
studies required at least 20 pack-years of smoking history. In
terms of background treatment, the studies allowed patients to
use a short-acting -agonist as needed for rescue medication. In
eneral, the four indacaterol studies for which the authors had
ccess to IPD seem relatively comparable to other COPD trials. As
uch, an MTC including all the evidence will probably not differ
ystematically from the results obtained with the current analysis.
n analysis combining results of these four IPD studies with other
D RCT evidence is required to assess this hypothesis given the
arge number of published studies for COPD. Of course, adjust-
ent for confounding bias due to consistency violations is com-
romised in such an elaborate analysis [15].
The patient population included in the different trials deter-
ines the external validity of the MTC. The RCTs included pa-
ients from Europe, North America, South America, and Austral-
sia, implying that the findings of the current analysis can be
onsidered relevant for patients with moderate to severe COPD
n these regions. This does not imply, however, that treatment
ffects are the same for all patients across or within these re-
ions. Hence, a limitation of the current analysis is that country
ffects were not taken into consideration. Such information
ould help specify the regions where current findings are most
ertinent.
The outcomes in this study are considered relevant to treat-
ents for COPD. FEV1 was the primary end point in all the studies
nd is also required from a regulatory perspective. Lung function
nd symptoms are the worst in the early morning and therefore
ffect patient functionality and daily activities [25,26]. Dyspnea
as been reported as the most disabling symptom [27], while SGRQ
epresents a key patient-reported outcome that provides direct
nsight into the overall health status of patients.
The improvements in trough FEV1 associated with indacaterol
0.16–0.17 L relative to placebo) can be considered clinically rele-
ant according to the threshold of 0.12 L prespecified in the RCTs
28]. In comparison to formoterol, the difference of 0.10 L and 0.11 L
ssociated with indacaterol 150 and 300 g, respectively, can alsobe considered clinically important based on the range proposed by
Cazzola et al. (0.10–0.14 L) [28]. In the INVOLVE study, however,
formoterol had less bronchodilation effect compared with earlier
studies, which may have been related to the higher FEV1 revers-
bility of patients (17%) in the previous trials [29,30]. Indacaterol
50 and 300 g also provided additional efficacy over salmeterol in
terms of FEV1 (0.05 L and 0.06 L, respectively), which is known to be
an effective bronchodilator, and could be compared with the im-
provement associated with tiotropium versus BID 2-agonists
0.40–0.50 L) [24,31]. Therefore, indacaterol is expected to be at
east as efficacious as tiotropium in terms of bronchodilation,
hich represents the “gold standard” bronchodilator in clinical
ractice in many countries [4].
Moreover, the benefits in lung function associated with inda-
aterol may allow greater activity, thereby improving the overall
ealth status [4]. Although the FEV1 improvements were main-
ained from 12 weeks to 6 months for indacaterol, the benefits in
erms of TDI decreased slightly at 6 months.
Some minor differences in efficacy were observed between the
wo doses of indacaterol, with a slight advantage for indacaterol
00 g in terms of FEV1 and TDI. SGRQ results appeared to favor
ndacaterol 150 g over indacaterol 300 g, but it should be noted
that the difference was not clinically meaningful and when the
two doses were included in the same underling RCT there was no
significant difference.
Two of the most recent MTCs published in COPD [32,33] were
ased on AD identified through systematic reviews performed in
007 and focused on the proportion of patients experiencing an ex-
cerbation. Authors acknowledge the limitations of this outcome,
hich is not adjusted for medication or trial duration, and identify
he need for IPD to evaluate the rate of exacerbations per year. Anal-
ses for the rate of exacerbation per patient-year were explored, but
esults should be interpreted with caution because the trial duration
as limited and the population was not recruited on the basis of
xacerbations. Results indicated that all active treatments were com-
arable and demonstrated improvements versus placebo, although
he rate of exacerbations in the placebo group was lower compared
ith that in the current literature. Longer-term trials that may allow
or IPD MTCs on the rate of exacerbations per patient-year are ongo-
ng.
Although the current MTC focused on lung function, dyspnea,
nd overall health status, identification of the “best” or most appro-
riate treatment cannot be made on the basis of efficacy end points
lone. To inform health care decision making for clinical treatment
uidelines and reimbursement policies, the efficacy findings must be
nterpreted in light of the safety profile of the compared interven-
ions and convenience. Compared with the BID dosing required for
almeterol and formoterol, the OD regimen for indacaterol may im-
rove adherence in clinical practice [34], which has been reported to
ange from rates as low as 10% to 40% for COPD medication [34–36].
In conclusion, based on an IPD MTC of four RCTs, indacaterol is
xpected to be comparable to formoterol, salmeterol, and tiotro-
ium. Indacaterol is expected to show greater improvement regard-
ng FEV1 than formoterol and salmeterol and a greater improvement
n health status than tiotropium as measured by the SGRQ total
core. The improvement in dyspnea with indacaterol 150 g was
comparable to that with other interventions, with indacaterol 300g
showing the greatest response of all the treatments.
Source of financial Support: This study was funded by Novartis.
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